Kunxian capsule alleviates podocyte injury and proteinuria by inactivating β-catenin in db/db mice

BackgroundDiabetic kidney disease (DKD) remains the primary cause of end-stage renal disease (ESRD) globally, but treatment options are limited. Kunxian capsule (KXC) has been utilized for the treatment of autoimmune diseases and IgA nephropathy in China. However, its effect on DKD remains poorly in...

全面介绍

书目详细资料

发表在:	Frontiers in Medicine
Main Authors:	Bo Jin, Jing Liu, Yan Zhu, Jian Lu, Qingyan Zhang, Yan Liang, Qiuyuan Shao, Chunming Jiang
格式:	文件
语言:	英语
出版:	Frontiers Media S.A. 2023-06-01
主题:	Kunxian capsule diabetic kidney disease podocyte β-Catenin epithelial-to-mesenchymal transition
在线阅读:	https://www.frontiersin.org/articles/10.3389/fmed.2023.1213191/full